financetom
Business
financetom
/
Business
/
Biden administration urges US Supreme Court to reject Musk appeal in SEC dispute
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Biden administration urges US Supreme Court to reject Musk appeal in SEC dispute
Mar 22, 2024 8:59 PM

WASHINGTON (Reuters) - President Joe Biden's administration on Friday urged the U.S. Supreme Court to turn away billionaire businessman Elon Musk's dispute with the Securities and Exchange Commission.

Musk in December asked the justices to take up his appeal after a lower court upheld his consent decree with the SEC that arose after he posted on Twitter, now called X, in 2018 that he had "funding secured" to take his electric car company Tesla private. The SEC accused Musk of defrauding investors.

Musk's agreement was part of a settlement with the SEC under which he and Tesla each paid $20 million fines, Musk gave up his role as Tesla's chairman and he agreed to let a Tesla lawyer approve some posts on Twitter. Musk bought the social media platform in 2022 and renamed it.

Musk has called the consent decree a "muzzle" on his constitutional free speech rights.

The Justice Department in its filing said that "the settlement term here was reasonably designed to minimize the likelihood that petitioner (Musk) would make future false or misleading statements in violation of the securities laws."

A three-judge panel of the Manhattan-based 2nd U.S. Circuit of Appeals rejected Musk's claim that the SEC exploited the decree to conduct harassing investigations into his use of Twitter.

In its ruling, the 2nd Circuit decided Musk could not revisit the screening of Twitter posts on grounds that he had "changed his mind." The 2nd Circuit in July 2023 denied Musk's request to rehear the case.

Musk's lawyers have said the SEC had no right to impose, as a condition of settling, a "gag rule" that they contend violated the U.S. Constitution's First Amendment constraints on governmental limits on free speech. In his December court filing, Musk's lawyers told the justices that authorizing the SEC to require that Musk gain pre-approval for certain social media posts had handed the agency "intolerable power."

In a separate legal action related to Musk, the New Orleans-based 5th U.S. Circuit Court of Appeals has agreed to reconsider its March decision that Musk violated federal labor law by posting on Twitter in May 2018 that Tesla employees would lose stock options if they joined a union. The 5th Circuit heard arguments in the case in January.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Halozyme Therapeutics Says VYVGART to Treat Rare Autoimmune Disease Receives CHMP Recommendation
Halozyme Therapeutics Says VYVGART to Treat Rare Autoimmune Disease Receives CHMP Recommendation
May 25, 2025
11:41 AM EDT, 04/28/2025 (MT Newswires) -- Halozyme Therapeutics ( HALO ) said Monday its license partner, argenx, received a positive opinion for VYVGART from the European Medicines Agency's Committee for Medicinal Products for Human Use to treat adults with chronic inflammatory demyelinating polyneuropathy. The subcutaneous injection of VYVGART is co-formulated with Halozyme's ENHANZE drug delivery technology. CIDP is a...
Update: Osisko Development Provides Optimized Feasibility Study Results for Cariboo Gold Project
Update: Osisko Development Provides Optimized Feasibility Study Results for Cariboo Gold Project
May 25, 2025
11:44 AM EDT, 04/28/2025 (MT Newswires) -- (Adds comment and updates shares.) Osisko Development ( ODV ) reported Monday the results of an optimized feasibility study for the Cariboo gold project in British Columbia. The company said the study supports the development of an $881-million mining project producing 190,000 ounces of gold annually over a 10-year mine life The study...
Guardant Health Launches Molecular Profiling Cancer Test
Guardant Health Launches Molecular Profiling Cancer Test
May 25, 2025
11:45 AM EDT, 04/28/2025 (MT Newswires) -- Guardant Health ( GH ) said Monday it launched its its molecular profiling test Guardant360 Tissue, which provides a more complete view of cancer. The tumor tissue test incorporates comprehensive multiomics analysis, including DNA, RNA, AI-powered PD-L1 and genome-wide methylation data, the company said. The test is covered by Medicare for eligible patients,...
Zentalis Pharmaceuticals Doses 1st Patient in Part 2 of Ovarian Cancer Clinical Trial
Zentalis Pharmaceuticals Doses 1st Patient in Part 2 of Ovarian Cancer Clinical Trial
May 25, 2025
11:41 AM EDT, 04/28/2025 (MT Newswires) -- Zentalis Pharmaceuticals ( ZNTL ) said Monday it has dosed the first patient in part 2 of the phase 2 clinical trial of azenosertib in ovarian cancer patients. The company said it expects to release topline data from part 2 by the end of 2026, adding that a successful trial can support an...
Copyright 2023-2025 - www.financetom.com All Rights Reserved